相关临床试验
62
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1871
进行中（未招募）
6
9.7%
已完成
28
45.2%
尚未招募
5
8.1%
招募中
22
35.5%
Unknown
1
1.6%
暂无批准数据
- Histotripsy is a noninvasive focused-ultrasound technique that mechanically destroys liver tumor tissue through cavitation bubble clouds, unlike thermal ablation methods. - The FDA cleared the first histotripsy system for liver tumors in 2023 based on the HOPE4LIVER trial, confirming short-term safety and technical success. - UAMS has become the first provider in Arkansas to offer histotripsy, with treatment sessions lasting about 20–30 minutes per tumor under general anesthesia on an outpatient basis. - Long-term efficacy data, including progression-free and overall survival, remain unevaluated, and the technology is currently limited to small, ultrasound-visible tumors.
- Researchers analyzed 77 multiple myeloma patients and found that low red blood cell parameters (RBC count, hemoglobin, hematocrit) before CAR-T cell collection were significantly associated with poor prognosis and shorter progression-free survival. - Pre-treatment albumin levels below 35.3 g/L emerged as the strongest predictor of treatment failure, with an area under the curve of 0.756 and patients in the low albumin group showing significantly shorter progression-free survival. - A separate study of 110 patients revealed that CD4+/CD8+ ratios below 1.0 at apheresis and elevated CD8+ T cell levels were associated with lower response rates at day 90 following BCMA CAR-T therapy.
- The European Medicines Agency granted PRIME designation to NRTX-1001, recognizing its potential to address significant unmet medical needs in drug-resistant focal epilepsy treatment. - Clinical trial data showed a 92% median reduction in disabling seizures and 80% responder rate with sustained seizure control lasting 18-24 months after single administration. - NRTX-1001 offers a minimally invasive alternative to destructive brain surgeries, potentially avoiding neurocognitive impairment risks associated with current surgical procedures. - Neurona is expanding clinical development to include patients without mesial temporal sclerosis and preparing for Phase 3 EPIC trial initiation in late 2025.
• Researchers at UT Health San Antonio have developed "chemical endocytic medicinal chemistry," a novel approach that could enable large-molecule drugs to be taken orally rather than intravenously. • The discovery leverages CD36 protein receptors on cell surfaces to facilitate cellular uptake of large and water-soluble drugs, potentially overcoming the blood-brain barrier for treating conditions like brain cancer and Alzheimer's disease. • This paradigm shift in drug delivery could revolutionize pharmaceutical development, resurrect previously abandoned drug candidates, and enable more personalized medicine based on patients' varying CD36 expression levels.
- The University of Arkansas for Medical Sciences (UAMS) has received a $2.2 million grant from the National Eye Institute (NEI). - The grant will fund research into how modulating the immune response through efferocytosis can benefit patients with retinopathy. - Dr. Abdel Fouda's lab will lead the study, exploring methods to enhance myeloid cell-mediated efferocytosis in treating retinopathy. - The research aims to develop new therapies for ischemic and trauma-induced retinopathy by understanding efferocytosis' role.
- A multicenter real-world study of 110 patients treated with teclistamab demonstrated a 62% overall response rate and 51% very good partial response rate, comparable to the pivotal MajesTEC-1 trial despite treating a more heavily pretreated population. - The incidence of severe cytokine release syndrome and neurotoxicity was substantially higher in real-world practice (3.6% and 4.5% respectively) compared to clinical trials (0.6% each), likely due to higher disease burden in routine practice. - Primary intravenous immunoglobulin prophylaxis significantly reduced infection rates by approximately 70%, with patients receiving IVIG showing lower cumulative incidence of grade 3 or higher infections compared to those without prophylaxis. - Analysis of FDA adverse event data across BCMA-targeted therapies revealed teclistamab had the highest rates of life-threatening events and death, with infections being the predominant cause of non-relapse mortality.
